The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Open accessAbstract
BACKGROUND: SGLT2 inhibitors are strongly recommended in guidelines to treat patients with heart failure with reduced ejection fraction, but their clinical benefits at higher ejection fractions are less well established. Two large-scale trials, DELIVER and EMPEROR-Preserved, in heart failure with mildly reduced or preserved ejection fraction have been done, providing power to examine therapeutic effects on cardiovascular mortality and in patient subgroups when combined with the earlier trials in reduced ejection fraction. METHODS: We did a prespecified meta-analysis of DELIVER and EMPEROR-Preserved, and subsequently included trials that enrolled patients with reduced ejection fraction (DAPA-HF and EMPEROR-Reduced) and those admitted to hospital with worsening heart failure, irrespective of ejection fraction (SOLOIST-WHF). Using trial-level data with harmonised endpoint definitions, we did a fixed-effects meta-analysis to estimate the effect of SGLT2 inhibitors on various clinical endpoints in heart failure The primary endpoint for this meta-analysis was time from randomisation to the occurrence of the composite of cardiovascular death or hospitalisation for heart failure. We assessed heterogeneity in treatment effects for the primary endpoint across subgroups of interest. This study is registered with PROSPERO, CRD42022327527. FINDINGS: Among 12 251 participants from DELIVER and EMPEROR-Preserved, SGLT2 inhibitors reduced composite cardiovascular death or first hospitalisation for heart failure (hazard ratio 0·80 [95% CI 0·73-0·87]) with consistent reductions in both components: cardiovascular death (0·88 [0·77-1·00]) and first hospitalisation for heart failure (0·74 [0·67-0·83]). In the broader context of the five trials of 21 947 participants, SGLT2 inhibitors reduced the risk of composite cardiovascular death or hospitalisation for heart failure (0·77 [0·72-0·82]), cardiovascular death (0·87 [0·79-0·95]), first hospitalisation for heart failure (0·72 [0·67-0·78]), and all-cause mortality (0·92 [0·86-0·99]). These treatment effects for each of the studied endpoints were consistently observed in both the trials of heart failure with mildly reduced or preserved ejection fraction and across all five trials. Treatment effects on the primary endpoint were generally consistent across the 14 subgroups examined, including ejection fraction. INTERPRETATION: SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisations for heart failure in a broad range of patients with heart failure, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction or care setting. FUNDING: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These drug classes are recommended as glucose-lowering therapy for individuals with cardiovascular disease or risk factors6,7 on the basis of randomized clinical trial evidence demonstrating a reduction in cardiovascular events (SGLT2is and GLP-1RAs)14,15,16 or suggesting cardiovascular benefit (metformin and pioglitazone).17,18”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a large meta-analysis (308) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death,”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [308]
The cited source says what the claim attributes to it.
In the citing paper
“A large meta-analysis (297) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and SOLOIST-WHF trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, first hospitalization for heart failure, and all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
The cited source says what the claim attributes to it.
In the citing paper
“The findings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all five trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [535]
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“A large recent meta-analysis (227) including data from EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and Effect of Sotagli fl ozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOISTWHF) included 21,947 patients and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, fi r”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
In the citing paper
“The fi ndings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all fi ve trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Self-citationSolomon, S. D., Anavekar, N. S., Skali, H., McMurray, J. J. V., Swedberg, K. B., Yusuf, S., Granger, C. B., Michelson, E. L., Wang, D., Pocock, S., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.561423 · Cited by 873
Self-citation
Research works printed but not linked: 1
- Zannad, 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, 819, 10.1016/S0140-6736(20)31824-9 · DOI · Paper page
Cited by
Sorted by citations
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad195 · Cited by 2,612
Self-citationCardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
Self-citation2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Cuartas, M. M., Abreu, A., Adamo, M., Marsan, N. A., Barili, F., Bonaros, N. E., Cosyns, B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf194 · Cited by 1,364
Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02074-8 · Cited by 1,020
Self-citationHeart Failure With Preserved Ejection Fraction: A Review
Redfield, M. M., & Borlaug, B. A. (2023) · JAMA · doi:10.1001/jama.2023.2020 · Cited by 662
Kittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
Cardiovascular risk in diabetes mellitus: Epidemiology, assessment and prevention
Wong, N. D., & Sattar, N. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00877-z · Cited by 495
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3024 · Cited by 512
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Self-citationFrom geroscience to precision geromedicine: Understanding and managing aging
Kroemer, G., Maier, A. B., Cuervo, A. M., Gladyshev, V. N., Ferrucci, L., Gorbunova, V., Kennedy, B. K., Rando, T. A., Seluanov, A., Sierra, F., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.011 · Cited by 395
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339
Self-citationHeart failure with preserved ejection fraction: everything the clinician needs to know
Campbell, P. C., Rutten, F. H., Lee, M. M. Y., Hawkins, N. M., & Petrie, M. C. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02756-3 · Cited by 294
Hegemony of inflammation in atherosclerosis and coronary artery disease
Attiq, A., Afzal, S., Ahmad, W., & Kandeel, M. K. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176338 · Cited by 251
Beghini, A., Sammartino, A. M., Papp, Z. L., von Haehling, S., Biegus, J., Ponikowski, P. P., Adamo, M., Falco, L., Lombardi, C., Pagnesi, M., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14857 · Cited by 229
Patel, S. M., Kang, Y. M., Im, K., Neuen, B. L., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Claggett, B. L., Fletcher, R. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069568 · Cited by 222
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 275
Anker, S. D., Usman, M., Anker, M. S., Butler, J., Böhm, M., Abraham, W. T., Adamo, M., Chopra, V., Cicoira, M., Cosentino, F., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2894 · Cited by 215
Heart failure with preserved ejection fraction
HAMO, C. E., DeJong, C., Hartshorne‐Evans, N., Lund, L. H., Shah, S. J., Solomon, S. D., & Lam, C. S. P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00540-y · Cited by 197
Self-citationSGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Preda, A., Montecucco, F., Carbone, F., Camici, G. G., Lüscher, T. F., Kraler, S. C., & Liberale, L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae047 · Cited by 210
Peikert, A., Martínez, F. A., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., de Boer, R. A., DeMets, D. L., Hernandez, A. F., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.010080 · Cited by 151
Self-citationCausland, F. R. M., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., de Boer, R. A., Docherty, K. F., Fang, J. C., Hernandez, A. F., Inzucchi, S. E., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4210 · Cited by 152
Self-citationGourdy, P., Darmon, P., Diévart, F., Halimi, J., & Guerci, B. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01798-4 · Cited by 141
Akerman, A. P., Porumb, M., Scott, C. G., Beqiri, A., Chartsias, A., Ryu, A. J., Hawkes, W., Huntley, G. D., Arystan, A. Z., Kane, G. C., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100452 · Cited by 118
Neurohumoral Activation in Heart Failure
Manolis, A. S., Manolis, T. A., & Manolis, A. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015472 · Cited by 117
Pandey, A. K., Bhatt, D. L., Pandey, A. K., Marx, N., Cosentino, F., Pandey, A., & Verma, S. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad389 · Cited by 125
Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
Yeoh, S. E., Osmanska, J., Petrie, M. C., Brooksbank, K. J. M., Clark, A. L., Docherty, K. F., Foley, P. W. X., Guha, K., Halliday, C. A., Jhund, P. S., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad341 · Cited by 110
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107
Applications of SGLT2 inhibitors beyond glycaemic control
O’Hara, D. V., Lam, C. S. P., McMurray, J. J. V., Yi, T. W., HOCKING, S. L., Dawson, J., Raichand, S., Januszewski, A. S., & Jardine, M. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00836-y · Cited by 123
Self-citationState-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications
Vallon, V. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae092 · Cited by 119
Marfella, R., Sardu, C., D’Onofrio, N., Fumagalli, C., Scisciola, L., Sasso, F. C., Siniscalchi, M., Marfella, L. V., D’Andrea, D., Minicucci, F., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02781-2 · Cited by 101
Packer, M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad235 · Cited by 100
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
Seminer, A., Mulihano, A., O’Brien, C., Krewer, F., Costello, M., Judge, C., O’Donnell, M., & Reddin, C. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0360 · Cited by 91
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Butler, J., Abildstrom, S. Z., Borlaug, B. A., Davies, M. J., Kitzman, D. W., Petrie, M. C., Shah, S. J., Verma, S., Abhayaratna, W. P., Chopra, V., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.09.811 · Cited by 95
Self-citationBechmann, L. E., Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117236 · Cited by 87
Amdani, S. M., Conway, J. L., George, K., Martinez, H. R., Asante‐Korang, A., Goldberg, C. S., Davies, R. R., Miyamoto, S. D., & Hsu, D. T. (2024) · Circulation · doi:10.1161/cir.0000000000001245 · Cited by 91
Packer, M., Butler, J., Zeller, C., Pocock, S. J., Brueckmann, M., Ferreira, J. P., Filippatos, G., Usman, M. S., Zannad, F., & Anker, S. D. (2023) · Circulation · doi:10.1161/circulationaha.123.065748 · Cited by 86
Fauchier, L., Bisson, A., & Bodin, A. (2023) · BMC Medicine · doi:10.1186/s12916-023-02764-3 · Cited by 90
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Cuartas, M. M., Abreu, A., Adamo, M., Marsan, N. A., Barili, F., Bonaros, N. E., Cosyns, B., et al. (2025) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaf276 · Cited by 97
Judge, P. K., Tuttle, K. R., Staplin, N., Hauske, S. J., Zhu, D., Sardell, R. J., Cronin, L., Green, J. B., Agrawal, N., Arimoto, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae263 · Cited by 84
Self-citationMarfella, R., Prattichizzo, F., Sardu, C., Rambaldi, P. F., Fumagalli, C., Marfella, L. V., Grotta, R. L., Frigé, C., Pellegrini, V., D’Andrea, D., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02118-6 · Cited by 92
How to Manage Heart Failure With Preserved Ejection Fraction
Desai, A. S., Lam, C. S. P., McMurray, J. J. V., & Redfield, M. M. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.03.011 · Cited by 83
Self-citationPredicting and preventing heart failure in type 2 diabetes
Pandey, A., Khan, M. S., Patel, K. V., Bhatt, D. L., & Verma, S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00128-6 · Cited by 84
Cardiovascular Disease in Diabetes and Chronic Kidney Disease
Swamy, S., Noor, S. M., & Mathew, R. O. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12226984 · Cited by 88
Renal-Cardiac Crosstalk in the Pathogenesis and Progression of Heart Failure
Noels, H., van der Vorst, E. P. C., Rubin, S., Emmett, A., Marx, N., Tomaszewski, M., & Jankowski, J. (2025) · Circulation Research · doi:10.1161/circresaha.124.325488 · Cited by 92
Docherty, K. F., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Mueller, K., Viswanathan, P., Scalise, A. V., Lam, C. S. P., Senni, M., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.072011 · Cited by 79
Self-citationEndothelial cell metabolism in cardiovascular physiology and disease
Pasut, A., Lama, E., Van Craenenbroeck, A. H., Kroon, J., & Carmeliet, P. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01162-x · Cited by 74
Roddick, A., Wonnacott, A., Webb, D. R., Watt, A., Watson, M. A., Staplin, N., Riding, A., Lioudaki, E., Kuverji, A., Kossi, M. E., et al. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03339-3 · Cited by 78
Obesity accelerates cardiovascular ageing
Ruperez, C., Madeo, F., de Cabo, R., Kroemer, G., & Abdellatif, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf216 · Cited by 73
Vardeny, O., Fang, J. C.-T., Desai, A. S., Jhund, P. S., Claggett, B. L., Vaduganathan, M., de Boer, R. A., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02102-9 · Cited by 85
Self-citationPatel, R. P., Wadid, M., Makwana, B., Kumar, A., Khadke, S., Bhatti, A. W., Banker, A., Husami, Z., Labib, S. B., Venesy, D. M., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.07.006 · Cited by 79
Self-citationPacker, M. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.10.004 · Cited by 73
Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure
Modzelewski, K. L., Pipilas, A. R., & Bosch, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.9305 · Cited by 71
Vaduganathan, M., Claggett, B. L., Kulac, I. J., Miao, Z. M., Desai, A. S., Jhund, P. S., Henderson, A. D., BRINKER, M. D., Lay‐Flurrie, J., Viswanathan, P., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.072055 · Cited by 75
Self-citationMitsas, A. C., Elzawawi, M., Mavrogeni, S. I., Boekels, M., Khan, A. A., Eldawy, M., Stamatakis, I., Kouris, D., Daboul, B., Gunkel, O., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237041 · Cited by 77
Lv, R., Xu, L., Che, L., Liu, S., Wang, Y., & Dong, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1125693 · Cited by 74
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 101
Desai, R. J., Wang, S. V., Sreedhara, S. K., Zabotka, L. E., Khosrow‐Khavar, F., Nelson, J. C., Shi, X., Toh, S., Wyss, R., Patorno, E., et al. (2024) · BMJ · doi:10.1136/bmj-2023-076460 · Cited by 69
Mutruc, V., Bologa, C., Șorodoc, V., Ceasovschih, A., Morărașu, B. C., Șorodoc, L., Catar, O., & Lionte, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082833 · Cited by 79
Current concepts in coronary artery revascularisation
Gaudino, M. F. L., Andreotti, F., & Kimura, T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00459-2 · Cited by 67
COHEN, L. P., Isaza, N., Hernandez, I., Lewis, G. D., Ho, J. E., Fonarow, G. C., Kazi, D. S., & Bellows, B. K. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.0077 · Cited by 65
New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy
Gallo, G., Lanza, O., & Savoia, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065089 · Cited by 74
Recent successes in heart failure treatment
Lam, C. S. P., Docherty, K. F., Ho, J. E., McMurray, J. J. V., Myhre, P. L., & Omland, T. (2023) · Nature Medicine · doi:10.1038/s41591-023-02567-2 · Cited by 68
Self-citationHeart Failure: An Update from the Last Years and a Look at the Near Future
Riccardi, M., Sammartino, A. M., Piepoli, M. F., Adamo, M., Pagnesi, M., Rosano, G. M. C., Metra, M., von Haehling, S., & Tomasoni, D. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14257 · Cited by 66
Fatima, A., Rasool, S., Devi, S., Talha, M., Waqar, F., Nasir, M. I., Khan, M. R., Jaffari, S. M. I. A., Haider, A., Shah, S. U., et al. (2023) · Cureus · doi:10.7759/cureus.46243 · Cited by 72
Self-citation2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 109
Self-citationMcMurray, J. J. V., Docherty, K. F., de Boer, R. A., Hammarstedt, A., Kitzman, D. W., Kosiborod, M. N., Maria Langkilde, A., Reicher, B., Senni, M., Shah, S. J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065061 · Cited by 60
Self-citationCost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
Zheng, J., Parizo, J. T., Spertus, J. A., Heidenreich, P. A., & Sandhu, A. T. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.5010 · Cited by 63
Henry, A., Mo, X., Finan, C., Chaffin, M. D., Speed, D., Issa, H. G., Denaxas, S., Ware, J. S., Zheng, S. L., Mälarstig, A., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02064-3 · Cited by 71
Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction
Tavares, C. A. M., Azevedo, L. C. P., Réa-Neto, Á., Campos, N. S., Amêndola, C. P., Kozesinski-Nakatani, A. C., David-João, P. G., Lobo, S. M., Filiponi, T. C., de Almeida, G. M. B., et al. (2024) · JAMA · doi:10.1001/jama.2024.10510 · Cited by 58
Self-citationSGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080322 · Cited by 65
Lang, F., Teruya, S. L., Weinsaft, A., Cuomo, M., Santos, A. M., Nalbandian, A., Bampatsias, D., & Maurer, M. S. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3198 · Cited by 57
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD
Mayne, K. J., Staplin, N., Keane, D. F., Wanner, C., Brenner, S., Cejka, V., Stegbauer, J., Judge, P. K., Preiss, D., Emberson, J., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000271 · Cited by 58
Frailty, Sarcopenia, Cachexia, and Malnutrition in Heart Failure
Maeda, D., Fujimoto, Y., Nakade, T., Abe, T., Ishihara, S., Jujo, K., & Matsue, Y. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2024.0089 · Cited by 57
Rosano, G. M. C., Teerlink, J. R., Kinugawa, K., Bayés‐Genís, A., Chioncel, O. D., Fang, J. C.-T., Greenberg, B., Ibrahim, N. E., Imamura, T., Inomata, T., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3646 · Cited by 60
Kondo, T., Dewan, P., Anand, I. S., Desai, A. S., Packer, M., Zile, M. R., Pfeffer, M. A., Solomon, S. D., Abraham, W. T., Shah, S. J., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063642 · Cited by 54
Self-citationPharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction
Zafeiropoulos, S., Farmakis, I. T., Milioglou, I., Doundoulakis, I., Gorodeski, E. Z., Konstantinides, S., Cooper, L. B., Zanos, S. P., Stavrakis, S., Giamouzis, G., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.07.014 · Cited by 58
Vascular (dys)function in the failing heart
Liberale, L., Duncker, D. J., Hausenloy, D. J., Kraler, S. C., Bøtker, H. E., Podesser, B. K., Heusch, G., & Kleinbongard, P. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01163-w · Cited by 58
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
Youn, J., Kim, D., Cho, J. Y., Cho, D., Park, S. M., Jung, M., Hyun, J., Cho, H., Park, S., Choi, J., et al. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0011 · Cited by 53
Where Are We With Treatment and Prevention of Heart Failure in Patients Post–Myocardial Infarction?
Carberry, J., Marquis‐Gravel, G., O’Meara, E., & Docherty, K. F. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.025 · Cited by 49
Self-citationMroueh, A., Algara‐Suárez, P., Fakih, W., Gong, D.-S., Matsushita, K., Park, S., Amissi, S., Auger, C., Kauffenstein, G., Meyer, N., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae257 · Cited by 49
Banerjee, M., Maisnam, I., Pal, R., & Mukhopadhyay, S. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad522 · Cited by 49
Immunomodulation and immunopharmacology in heart failure
Markousis‐Mavrogenis, G., Baumhove, L., Al‐Mubarak, A. A., Aboumsallem, J. P., Bömer, N., Voors, A. A., & van der Meer, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00919-6 · Cited by 51
Heart failure management guidelines: New recommendations and implementation
Heidenreich, P. A. (2023) · Journal of Cardiology · doi:10.1016/j.jjcc.2023.10.009 · Cited by 51
Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy
Nakamura, M. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.12568 · Cited by 53
Lund, L. H., Lam, C. S. P., Pizzato, P. E., Gabrielsen, A., Michaëlsson, E., Nelander, K., Ericsson, H., Holden, J., Folkvaljon, F., Mattsson, A., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2977 · Cited by 48
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
Docherty, K. F., Lam, C. S. P., Rakisheva, A., Coats, A. J. S., Greenhalgh, T., Metra, M., Petrie, M. C., & Rosano, G. M. C. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2946 · Cited by 58
Self-citationSawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 50
Savarese, G., Schiattarella, G. G., Lindberg, F., Anker, M. S., Bayés‐Genís, A., Bäck, M., Braunschweig, F., Bucciarelli‐Ducci, C., Butler, J., Cannata, A. N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3676 · Cited by 52
Self-citationOstrominski, J. W., Thierer, J. M., Claggett, B. L., Miao, Z. M., Desai, A. S., Jhund, P. S., Kosiborod, M., Lam, C. S. P., Inzucchi, S. E., Martínez, F. A., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.05.015 · Cited by 48
Self-citationYen, F., Wang, S., Hsu, C.-C., Hwu, C., & Wei, J. C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.16578 · Cited by 47
Inzucchi, S. E., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Kosiborod, M., Lam, C. S. P., Martínez, F. A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00308-4 · Cited by 51
Self-citationRemnant cholesterol in patients admitted for acute coronary syndromes
Cordero, A., Álvarez, B. Á., Escribano, D., García‐Acuña, J. M., Cid-Álvarez, B. A., Rodríguez‐Mañero, M., Quintanilla, M. A., Agra-Bermejo, R., Zuazola, P., & González‐Juanatey, J. R. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac286 · Cited by 44
Rossi, V. A., Gruebler, M. R., Monzo, L., Galluzzo, A., & Beltrami, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076838 · Cited by 44
Packer, M. (2023) · American Journal of Nephrology · doi:10.1159/000531084 · Cited by 44
Kani, R., Watanabe, A., Miyamoto, Y., Ejiri, K., Iwagami, M., Takagi, H., Slipczuk, L. N., Tsugawa, Y., Aikawa, T., & Kuno, T. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031805 · Cited by 46
Metadata
- Authors
- Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D.
- Affiliations
- Brigham and Women's Hospital (US)
- British Heart Foundation (GB)
- Duke Medical Center (US)
- Yale University (US)
- University of Missouri–Kansas City (US)
- National University of Singapore (SG)
- Northwestern University (US)
- Corresponding author
- Solomon, Scott D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 400
- Issue
- 10354
- Pages
- 757-767
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4293353625
- Cited by
- 996
- References
- 24
- Citations by year
- 2026: 215 · 2025: 203 · 2024: 279 · 2023: 257 · 2022: 42
- FWCI
- 39.76
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-14)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, public-domain)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (acceptedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, public-domain)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company (NCT03057951)
- Pfizer
- AstraZeneca
- Sanofi
- National Institutes of Health
- Defense Acquisition Program Administration
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, all-cause mortality, subgroup analysis, DAPA-HF, EMPEROR-Preserved, EMPEROR-Reduced, cardiovascular risk stratification, treatment effect heterogeneity
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure, Hospitalization, Humans, Stroke Volume, Randomized Controlled Trials as Topic, Ventricular Function, Left, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
